loader2
Partner With Us NRI

Divis Laboratories Ltd share Price

Company details

3,685.00
3,742.00
2,730.00
3,934.70
6M Return 33.86%
1Y Return 3.68%
Mkt Cap.(Cr) 98,357.59
Volume 190,002
Div Yield 0.81%
OI
-
OI Chg %
-
Volume 190,002

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Margins tumble to historical low; outlook cautious…
About The Stock

    Divi’s is engaged in manufacturing generic APIs and intermediates, custom synthesis (CS) of active ingredients and advanced intermediates for pharma MNCs, other speciality chemicals like Carotenoids and complex compounds like peptides and Nucleotide revenues.

    • In CS, the company maintains strong relationship with global big pharma players while in generics it enjoys significant market share in products like Naproxen, Dextromethorphan and Gabapentin among others
    • Divi’s is fully backward integrated in products with high market share. The management intends to follow suit in other products
Q3FY22

    Beat estimates on back of strong order-book of custom synthesis.

    • Sales were up 46.5% YoY to ₹ 2493.2 crore
    • EBITDA was at ₹ 1097.2 crore, up 58.7% YoY with margins at 44%
    • Consequent PAT was at ₹ 902.2 crore (up 91.7% YoY)

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Divi's Laboratories announced Q1FY24 results:

  • Total income of Rs 1,859 crore for Q1FY24 on a consolidated basis as against an income of Rs 2,343 crore for Q1FY23.
  • Profit before Tax (PBT) for Q1FY24 amounted to Rs 492 crore as against a PBT of Rs 852 crore for Q1FY23 and a PBT of Rs 466 crore for Q4FY23.
  • The Company earned a Profit after Tax (PAT) of Rs 356 crore for Q1FY24 as against a PAT of Rs 702 crore for Q1FY23. PAT for Q4FY23 was Rs 321 crore.
  • Forex gain for Q1FY24 amounted to Rs 3 crore as against a gain of Rs 56 crore during Q1FY23.

 

 

Result PDF

View Other Company Results

OUR RESEARCH VIEW

Investment recommendation
Margins tumble to historical low; outlook cautious…
Call Date
03 Feb 2023
Entry Price 2,860.00
Target Price 2,945.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Divis Laboratories Ltd Stocks COMPARISION

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 12,767.09 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 18,676.55 -6,386.02
LAST 3M 37,244.98 6,086.45
LAST 6M 47,342.46 153,492.54
LAST 12M 133,811.11 156,210.35

Divis Laboratories Ltd Information

Stock PE (TTM)
66.6
Promoter Holding
51.93%
Book Value
480.9267
ROCE
19.3%
ROE
14.89%
Registered Address

1-72-23(P)/DIVIS/303 Divi Towe, Cyber Hills Gachibowli, Hyderabad, Telangana, 500032

Tel : 91-40-23786300/23786352/400
Email : mail:divislabs.com
Website : http://www.divislaboratories.com
Registrar

Karvy Computershare Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 532488
NSE Code : DIVISLAB
Book Closure Date (Month) :
BSE Group : A
ISIN : INE361B01024

FAQ’s on Divis Laboratories Ltd Shares

You can buy Divis Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Divis Laboratories Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Sep 22, 2023 03:56 PM the closing price of Divis Laboratories Ltd was ₹ 3,705.05.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Sep 22, 2023 03:56 PM, the market cap of Divis Laboratories Ltd stood at ₹ 98,357.59.

The latest PE ratio of Divis Laboratories Ltd as of Sep 22, 2023 03:56 PM is 66.6

The latest PB ratio of Divis Laboratories Ltd as of Sep 22, 2023 03:56 PM is 0.13

The 52-week high of Divis Laboratories Ltd is ₹ 3,934.70 while the 52-week low is ₹ 2,730.00

According to analyst recommendations, Divis Laboratories Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app